The ultimate goal of our laboratory is to develop novel strategies to overcome immunosuppression in ovarian and breast cancers. We have unique systems set up in our laboratory for high throughput tumour immune profiling and therapeutic assessment of novel compounds in immune competent mouse models of ovarian cancer. We specialise in in vivo application of RNAi therapeutics and utilise bioinformatic approaches to identify novel targets for treatment of cancer.
 

Services

High throughput immune profiling of tumours
We have systems set up for high throughput tumourimmune assessment. This includes assessment of thenumber and function of immune cells present in solidtumours. Typical immune cell types assessed are Bcells, T helper cells, Tregs, CD8 T-cells, dendritic cells,macrophages, NK cells, NKT cells, and myeloid derivedsuppressive cells. The assay will allow researchers toefficiently identify major immune cell populationsaffected by certain therapeutics.

In vivo nanoparticle delivery of RNAi therapeutics
We have unique systems set up for studying thebiological function of RNAi therapeutics (e.g.,siRNA, microRNA) in cancer mouse models. This will facilitate the understanding of biological consequences of switching off or turning on specific coding or non-coding RNAs.

Mouse models of cancer (ovarian cancer)
Our laboratory has multiple orthotopic mousemodels of ovarian cancer set up for studyingtherapeutic activity of novel compounds. Weroutinely perform assays to investigate impact oftherapeutics on blood vessel density, immune cellinfiltration, proliferation and apoptosis in tumours.

Characterisation of extracellular vesicles
We have systems set up for extracting extracellularvesicles from biological fluids. We perform severaldownstream assessments of these extracellularvesicles including functional testings and RNA/protein expression analyses.

Pathway enrichment bioinformatics analysis
We utilise bioinformatic pathway enrichmentstrategies to identify novel targets for cancertreatment. We routinely perform gene enrichmentanalyses to understand molecular mechanisms bywhich certain cancer therapeutics function.